Cholesterol and triglycerides is the main area connected here, and any felt benefit should be read together with the human evidence base.
The 67.7 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the C tier remains conservative.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Digestion and gut health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.
This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.
This range includes studies in specific patient groups. It is not a general dose or recommendation.
Standalone side-effect signals and combination cautions are listed separately.
Paper IDs and full lists are private. Only study types and summaries are shown.
Functional foods with plant sterols/stanols may be considered in individuals with high cholesterol levels at intermediate or low global cardiovascular risk who do not qualify for pharmacotherapy and as an adjunct to pharmacologic therapy in high and very high
The LDL-cholesterol-lowering effect of both plant sterols and stanols continues to increase up to intakes of approximately 3 g/d to an average effect of 12 %, with clear and comparable dose–response relationships observed.
Plant sterol containing products reduced LDL concentrations but the reduction was related to individuals’ baseline LDL levels, food carrier, and frequency and time of intake, and the observed differences between trial results were unlikely to have been caused
These findings indicate that the decreased intestinal absorption of cholesterol and carotenoids by plant sterols and stanols is caused by two distinct mechanisms, which could be explained by the effects of the 4-desmethyl family and 4,4-dimethylsterols on mice
Although phytosterols decrease LDL-cholesterol levels, there is no evidence that they reduce the risk of cardiovascular diseases; on the contrary, some studies suggest an increased risk of atherosclerosis with increasing serum levels of phytesterols.
A general overview of the available evidence regarding the beneficial physiological and pharmacological activities of phytosterol activities is provided, with special emphasis on their therapeutic potential for human health and safety.